Compare DENTSPLY SIRONA Inc (XRAY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DENTSPLY SIRONA Inc vs Zoetis Inc — how do they compare? DENTSPLY SIRONA Inc trades at $10.7 (market cap $2.14B), while Zoetis Inc trades at $73.83 (market cap $30.29B). The key difference: Zoetis Inc is far larger — about 14.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| XRAY | ZTS | |
|---|---|---|
Market Cap | $2.14B | $30.29B |
Sector | Health | Health |
52-Week High | $14.68 | $150.61 |
52-Week Low | $9.64 | $71.91 |
Enterprise Value | $4.21B | $37.86B |
Dividend Yield | 5.04% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XRAY trades at $10.99, down 3.43% on the day, reflecting ongoing pressure from declining revenues and negative profitability. The stock shows a bearish technical signal, with key support at $10. Recent Q2 2026 earnings beat estimates but sales fell 4.1%, highlighting persistent challenges in dental markets. Cash flow improved in 2025, yet net losses and high debt levels remain concerns.
The outlook is cautious; while analyst consensus suggests modest upside to a $12.50 target, weak margins, falling sales, and potential fiduciary scrutiny pose significant risks. Recovery depends on successful execution of the company's turnaround plan amid competitive and macroeconomic headwinds.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
